Literature DB >> 17962972

Treatment with laser CO2 cordectomy and clinical implications in management of mild and moderate laryngeal precancerosis.

A Minni1, M Barbaro, G Rispoli, F Diaferia, D Bernardeschi, R Filipo.   

Abstract

All the classification of precancerous lesions are based on the progression of specific histopathological characteristics, which in turn considers the grade of epithelial hyperplasia and dysplasia, nevertheless the transformation of laryngeal keratosis into carcinoma occurs through progressive modifications of normal epithelium in keratosis without dysplasia, to the point of degenerating into carcinoma in situ. The treatment of laringeal precancerosis has not yet defined a gold standard: according to some authors, a simple excision biopsy may be sufficient, others, instead, perform the stripping of the involved vocal cord, while others yet perform vaporization by means of CO2 laser. The aim of this paper is to evaluate and possibly validate the treatment of mild and moderate laryngeal dysplasia (LIN1-2) by CO2 laser, with particular attention to oncological and functional results. Fifty-eight patients (44 males and 14 females, mean age 54.3 years) affected by mild and moderate dysplasia (32 LIN I and 26 LIN II) diagnosed by a bioptic exam, were treated by performing a CO2 laser cordectomy (following the European Society of Laryngology's criteria). Before surgery to the patients was given a questionnaire to identify primary risk factors such as smoking, alcohol use and gastroesophageal reflux, were also handed a Vocal Performance Questionnaire. In all patients was performed a pH measurement over a 24-h period, a voice evaluation using a Kay digital Strobe 920. 84% of patients were smokers; the presence of reflux was reported in 11 patients (19%). The 32 LIN1 cases treated with type I cordectomy determined four recurrences (12.4%), of which two LIN1, one LIN2 and one carcinoma in situ. Of the 26 LIN2 cases examined, the 12 treated with type 1 cordectomy generated 1 recurrence alone with the presence of an invasive carcinoma (T1a) (8.3%), while no recurrences were reported in the group of 14 LIN2 cases treated with type II cordectomy. 93.1% (54/58) of cases showed a complete closing of the glottal plane over time. Considering the results in terms of disease control, and functional outcomes, our experience suggests subepithelial cordectomy (ELS I) for LIN 1 and subligament cordectomy (ELS II) for LIN 1 recurrences; therefore we suggest subligament cordectomy (ELS II) in LIN 2 cases.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17962972     DOI: 10.1007/s00405-007-0480-0

Source DB:  PubMed          Journal:  Eur Arch Otorhinolaryngol        ISSN: 0937-4477            Impact factor:   2.503


  26 in total

1.  What is the earliest non-invasive malignant lesion of the larynx?

Authors:  A Ferlito; C Doglioni; A Rinaldo; K O Devaney
Journal:  ORL J Otorhinolaryngol Relat Spec       Date:  2000 Mar-Apr       Impact factor: 1.538

2.  [The classification and differential diagnosis of epithelial hyperplasia of the laryngeal mucosa on the basis of histomorphological features. II].

Authors:  O KLEINSASSER
Journal:  Z Laryngol Rhinol Otol       Date:  1963-05

3.  Significance of keratosis and dyskeratosis for classifying hyperplastic aberrations of laryngeal mucosa.

Authors:  V Kambic; N Gale
Journal:  Am J Otolaryngol       Date:  1986 Sep-Oct       Impact factor: 1.808

4.  Definition of leukoplakia and related lesions: an aid to studies on oral precancer.

Authors:  I R Kramer; R B Lucas; J J Pindborg; L H Sobin
Journal:  Oral Surg Oral Med Oral Pathol       Date:  1978-10

5.  Carcinoma in situ of the glottic larynx: excision or irradiation?

Authors:  C Nguyen; B Naghibzadeh; M J Black; L Rochon; G Shenouda
Journal:  Head Neck       Date:  1996 May-Jun       Impact factor: 3.147

6.  Oncological and functional results of CO2 laser cordectomy.

Authors:  M Policarpo; P Aluffi; F Brovelli; G Borello; F Pia
Journal:  Acta Otorhinolaryngol Ital       Date:  2004-10       Impact factor: 2.124

7.  Pre- and intraoperative assessment of mid-cord erythroleukoplakias: a prospective study on 52 patients.

Authors:  Giorgio Peretti; Cesare Piazza; Marco Berlucchi; Johnny Cappiello; Marco Giudice; Piero Nicolai
Journal:  Eur Arch Otorhinolaryngol       Date:  2003-06-03       Impact factor: 2.503

8.  Short, self-report voice symptom scales: psychometric characteristics of the voice handicap index-10 and the vocal performance questionnaire.

Authors:  Ian J Deary; Alison Webb; Kenneth Mackenzie; Janet A Wilson; Paul N Carding
Journal:  Otolaryngol Head Neck Surg       Date:  2004-09       Impact factor: 3.497

9.  Preoperative and postoperative voice in Tis-T1 glottic cancer treated by endoscopic cordectomy: an additional issue for patient counseling.

Authors:  Giorgio Peretti; Cesare Piazza; Cristiano Balzanelli; Maria C Mensi; Manuela Rossini; Antonino R Antonelli
Journal:  Ann Otol Rhinol Laryngol       Date:  2003-09       Impact factor: 1.547

Review 10.  Hyperplasia, keratosis, dysplasia and carcinoma in situ of the vocal cords--a follow-up study.

Authors:  H Hellquist; J Lundgren; J Olofsson
Journal:  Clin Otolaryngol Allied Sci       Date:  1982-02
View more
  3 in total

1.  MicroRNA-10a-5p and microRNA-34c-5p in laryngeal epithelial premalignant lesions: differential expression and clinicopathological correlation.

Authors:  Yanping Hu; Honggang Liu
Journal:  Eur Arch Otorhinolaryngol       Date:  2014-09-30       Impact factor: 2.503

2.  Photodynamic therapy for head and neck dysplasia and cancer.

Authors:  Nestor R Rigual; Krishnakumar Thankappan; Michele Cooper; Maureen A Sullivan; Thomas Dougherty; Saurin R Popat; Thom R Loree; Merrill A Biel; Barbara Henderson
Journal:  Arch Otolaryngol Head Neck Surg       Date:  2009-08

3.  Angiolytic laser stripping versus CO2 laser microflap excision for vocal fold leukoplakia: Long-term disease control and voice outcomes.

Authors:  Jae-Yol Lim; Young Min Park; Minsuk Kang; Seung Jin Lee; Kwangha Baek; Jina Na; Hong-Shik Choi
Journal:  PLoS One       Date:  2018-12-31       Impact factor: 3.240

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.